Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE: VER-01 vs Opioids in Chronic Low Back Pain
NCT05610813Phase 3Completed
- Sponsor
- Vertanical
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of VER-01 in Low back pain (LBP) (2 arms), sponsored by Vertanical. Primary endpoint: Risk of developing constipation at 190 days. Started Jun 2023; status: completed.
02
Drugs
VER-01
03
Conditions
Low back pain (LBP)
Beyond the preview
Go deeper on NCT05610813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610813.